Menu Search
Equities

Editas Medicine Inc

8EM:BER

Editas Medicine Inc

Actions
  • Price (EUR)8.21
  • Today's Change-0.005 / -0.06%
  • Shares traded83.00
  • 1 Year change-47.27%
  • Beta--
Data delayed at least 15 minutes, as of Jan 27 2023 07:05 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Editas Medicine, Inc. is a clinical-stage gene editing company. The Company is focused on developing transformative gene editing medicines to treat a range of serious diseases. It has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The Company is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The Company's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.

  • Revenue in USD (TTM)25.64m
  • Net income in USD-201.13m
  • Incorporated2013
  • Employees264.00
  • Location
    Editas Medicine Inc11 Hurley StCAMBRIDGE 02141-2110United StatesUSA
  • Phone+1 (617) 401-9000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.editasmedicine.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.